Bio Box Australia • Ep 4

Re-imagining Drug Development with AI: COVID-19 & Infectious Diseases


VIDEO: Bio Box Australia • Ep 4

With the emergence of COVID-19, a global effort to find promising drug candidates has led to broad spectrum of promising agents. However, beyond the identification of suitable therapies, there is a need to develop combination therapy regimens that are efficacious and accessible. To address this challenge, artificial intelligence (AI) has been explored, largely in the drug discovery space. However, it is important to note that drug discovery and drug development are distinct segments of the roadmap that should be seamlessly integrated to ensure that promising drug candidates can be optimally integrated into combination therapy regimens. This talk will discuss recent advances in the use of prospective experimental validation and an AI-based optimisation strategy to actionably pinpoint multi-drug regimens for COVID-19 and other indications.

Prof. Dean Ho, Provost’s Chair Professor, Director of The N.1 Institute for Health (N.1), Director of the Institute for Digital Medicine (WisDM), and Head of the Department of Biomedical Engineering at the National University of Singapore